Stockscreener 앱 받기
2.51
0.40%
0.010
시간 외 거래:
2.51
전일 마감가:
$2.50
열려 있는:
$2.5
하루 거래량:
60,557
Relative Volume:
1.22
시가총액:
$34.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.18%
1개월 성능:
-19.81%
6개월 성능:
-85.75%
1년 성능:
+0.00%
1일 변동 폭
$2.44
$2.54
1주일 범위
$2.42
$2.65
52주 변동 폭
$2.42
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
OKUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.51 | 34.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World
Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com
Evercore ISI starts OnKure stock with Outperform rating - Investing.com
Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India
OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com
OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia
OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa
OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India
OnKure Therapeutics CFO sells $9,177 in stock - Investing.com
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada
OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure discovers new PI3Kα inhibitors - BioWorld Online
What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings? - Defense World
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects - TipRanks
Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely? - Yahoo Finance
OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer - Defense World
OnKure Therapeutics Reports Progress and Financials - TipRanks
OnKure boosts R&D spending with cancer trial underway - BizWest
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating - Marketscreener.com
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer - TipRanks
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c) - TipRanks
OnKure Therapeutics, Inc. SEC 10-K Report - TradingView
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences - GlobeNewswire
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell? - Defense World
FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - Nasdaq
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Onkure Therapeutics Inc (OKUR) 재무 분석
Onkure Therapeutics Inc (OKUR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Onkure Therapeutics Inc 주식 (OKUR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
| Leonard Braden Michael | 10% Owner |
Sep 24 '24 |
Buy |
1.41 |
29,600 |
41,866 |
3,388,649 |
| Leonard Braden Michael | 10% Owner |
Sep 17 '24 |
Buy |
1.36 |
55,300 |
75,108 |
3,358,243 |
| Leonard Braden Michael | 10% Owner |
Sep 18 '24 |
Buy |
1.40 |
806 |
1,128 |
3,359,049 |
| Leonard Braden Michael | 10% Owner |
Sep 16 '24 |
Buy |
1.37 |
172,747 |
236,871 |
3,302,943 |
| Leonard Braden Michael | 10% Owner |
Sep 13 '24 |
Buy |
1.31 |
150,000 |
196,950 |
3,130,196 |
| Leonard Braden Michael | 10% Owner |
Sep 12 '24 |
Buy |
1.40 |
36,176 |
50,523 |
2,980,196 |
0.52%
0.52%
자본화:
|
볼륨(24시간):